-
2
-
-
0019945902
-
Negative symptoms in schizophrenia. Definition and reliability
-
Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788.
-
(1982)
Arch Gen Psychiatry.
, vol.39
, Issue.7
, pp. 784-788
-
-
Andreasen, N.C.1
-
3
-
-
79952122958
-
Toward the next generation of negative symptom assessments: The collaboration to advance negative symptom assessment in schizophrenia
-
Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37(2): 291-299.
-
(2011)
Schizophr Bull.
, vol.37
, Issue.2
, pp. 291-299
-
-
Blanchard, J.J.1
Kring, A.M.2
Horan, W.P.3
Gur, R.4
-
4
-
-
77749291977
-
Negative symptoms in schizophrenia: Avolition and Occam's razor
-
Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359-369.
-
(2010)
Schizophr Bull.
, vol.36
, Issue.2
, pp. 359-369
-
-
Foussias, G.1
Remington, G.2
-
5
-
-
77952108456
-
Intrinsic motivation and learning in a schizophrenia spectrum sample
-
Choi J, Medalia A. Intrinsic motivation and learning in a schizophrenia spectrum sample. Schizophr Res. 2010;118(1-3):12-19.
-
(2010)
Schizophr Res.
, vol.118
, Issue.1-3
, pp. 12-19
-
-
Choi, J.1
Medalia, A.2
-
6
-
-
0031776804
-
The role of negative symptoms and cognitive dysfunction in schizophrenia outcome
-
Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol. 1998;13(Suppl 3):S21-S26.
-
(1998)
Int Clin Psychopharmacol.
, vol.13
, Issue.SUUPL. 3
-
-
Tamminga, C.A.1
Buchanan, R.W.2
Gold, J.M.3
-
7
-
-
0033864933
-
Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment
-
Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry. 2000;157(9):1461-1466.
-
(2000)
Am J Psychiatry.
, vol.157
, Issue.9
, pp. 1461-1466
-
-
Peralta, V.1
Cuesta, M.J.2
Martinez-Larrea, A.3
Serrano, J.F.4
-
8
-
-
84870425171
-
Identifying persistent negative symptoms in first episode psychosis
-
Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry. 2012;12:224.
-
(2012)
BMC Psychiatry.
, vol.12
, pp. 224
-
-
Hovington, C.L.1
Bodnar, M.2
Joober, R.3
Malla, A.K.4
Lepage, M.5
-
9
-
-
81955167927
-
Persistent negative symptoms in first-episode schizophrenia: A prospective three-year follow-up study
-
Chang WC, Hui CL, Tang JY, et al. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res. 2011;133(1-3):22-28.
-
(2011)
Schizophr Res.
, vol.133
, Issue.1-3
, pp. 22-28
-
-
Chang, W.C.1
Hui, C.L.2
Tang, J.Y.3
-
10
-
-
79960818995
-
Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort
-
Mäkinen J, Miettunen J, Jääskeläinen E, Veijola J, Isohanni M, Koponen H. Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatr Res. 2010;178(1): 121-125.
-
(2010)
Psychiatr Res.
, vol.178
, Issue.1
, pp. 121-125
-
-
Mäkinen, J.1
Miettunen, J.2
Jääskeläinen, E.3
Veijola, J.4
Isohanni, M.5
Koponen, H.6
-
11
-
-
84858068941
-
No gender differences in social outcome in patients suffering from schizophrenia
-
Galderisi S, Bucci P, Üçok A, Peuskens J. No gender differences in social outcome in patients suffering from schizophrenia. Eur Psychiatry. 2012;27(6):406-408.
-
(2012)
Eur Psychiatry.
, vol.27
, Issue.6
, pp. 406-408
-
-
Galderisi, S.1
Bucci, P.2
Üçok, A.3
Peuskens, J.4
-
12
-
-
77950307734
-
Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study
-
CLAMORS Study Collaborative Group
-
Bobes J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280-286.
-
(2010)
J Clin Psychiatry.
, vol.71
, Issue.3
, pp. 280-286
-
-
Bobes, J.1
Arango, C.2
Garcia-Garcia, M.3
Rejas, J.4
-
13
-
-
0035971441
-
A five-year followup study of deficit and nondeficit schizophrenia
-
Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res. 2001;49(3):253-260.
-
(2001)
Schizophr Res.
, vol.49
, Issue.3
, pp. 253-260
-
-
Tek, C.1
Kirkpatrick, B.2
Buchanan, R.W.3
-
14
-
-
1642283731
-
Practice guideline for the treatment of patients with schizophrenia, second edition
-
for the American Psychiatric Association, Steering Committee on Practice Guidelines
-
Lehman AF, Lieberman JA, Dixon LB, et al; for the American Psychiatric Association, Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1-56.
-
(2004)
Am J Psychiatry.
, vol.161
, Issue.SUUPL. 2
, pp. 1-56
-
-
Lehman, A.F.1
Lieberman, J.A.2
Dixon, L.B.3
-
15
-
-
0028864078
-
The reliability of distinguishing primary versus secondary negative symptoms
-
Flaum M, Andreasen N. The reliability of distinguishing primary versus secondary negative symptoms. Compr Psychiatry. 1995;36(6): 421-427.
-
(1995)
Compr Psychiatry.
, vol.36
, Issue.6
, pp. 421-427
-
-
Flaum, M.1
Andreasen, N.2
-
16
-
-
0032697694
-
Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: A conflict of paradigms revisited
-
Peralta V, Cuesta MJ. Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited. Schizophr Res. 1999;40(3):245-253.
-
(1999)
Schizophr Res.
, vol.40
, Issue.3
, pp. 245-253
-
-
Peralta, V.1
Cuesta, M.J.2
-
17
-
-
35748969317
-
The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
-
Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602.
-
(2007)
Am J Psychiatry.
, vol.164
, Issue.10
, pp. 1593-1602
-
-
Buchanan, R.W.1
Javitt, D.C.2
Marder, S.R.3
-
18
-
-
52649164141
-
Negative symptoms in schizophrenia: A review
-
Mäkinen J, Miettunen J, Isohanni M, Koponen H. Negative symptoms in schizophrenia: a review. Nord J Psychiatry. 2008;62(5):334-341.
-
(2008)
Nord J Psychiatry.
, vol.62
, Issue.5
, pp. 334-341
-
-
Mäkinen, J.1
Miettunen, J.2
Isohanni, M.3
Koponen, H.4
-
19
-
-
84877115130
-
Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome
-
Galderisi S, Bucci P, Mucci A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 2013;147(1):157-162.
-
(2013)
Schizophr Res.
, vol.147
, Issue.1
, pp. 157-162
-
-
Galderisi, S.1
Bucci, P.2
Mucci, A.3
-
20
-
-
84886952819
-
Amotivation and functional outcomes in early schizophrenia
-
Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res. 2013;210(2):665-668.
-
(2013)
Psychiatry Res.
, vol.210
, Issue.2
, pp. 665-668
-
-
Fervaha, G.1
Foussias, G.2
Agid, O.3
Remington, G.4
-
21
-
-
84900456431
-
Negative symptoms across the schizophrenia spectrum: Phenomenological and neurobiological perspectives
-
In: Ritsner MS, editor. Volume II: Phenotypic and Endophenotypic Presentations. New York, NY: Springer
-
Foussias G, et al. Negative symptoms across the schizophrenia spectrum: Phenomenological and neurobiological perspectives. In: Ritsner MS, editor. Handbook of Schizophrenia Spectrum Disorders, Volume II: Phenotypic and Endophenotypic Presentations. New York, NY: Springer; 2011:1-32.
-
(2011)
Handbook of Schizophrenia Spectrum Disorders
, pp. 1-32
-
-
Foussias, G.1
-
22
-
-
77951573608
-
Anhedonia and emotional experience in schizophrenia: Neural and behavioral indicators
-
Dowd EC, Barch DM. Anhedonia and emotional experience in schizophrenia: neural and behavioral indicators. Biol Psychiatry. 2010;67(10):902-911.
-
(2010)
Biol Psychiatry.
, vol.67
, Issue.10
, pp. 902-911
-
-
Dowd, E.C.1
Barch, D.M.2
-
23
-
-
54149091651
-
Reward processing in schizophrenia: A deficit in the representation of value
-
Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 2008;34(5):835-847.
-
(2008)
Schizophr Bull.
, vol.34
, Issue.5
, pp. 835-847
-
-
Gold, J.M.1
Waltz, J.A.2
Prentice, K.J.3
Morris, S.E.4
Heerey, E.A.5
-
24
-
-
72449177826
-
The functional neuroanatomy of symptom dimensions in schizophrenia: A qualitative and quantitative review of a persistent question
-
Goghari VM, Sponheim SR, MacDonald AW 3rd. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev. 2010;34(3):468-486.
-
(2010)
Neurosci Biobehav Rev.
, vol.34
, Issue.3
, pp. 468-486
-
-
Goghari, V.M.1
Sponheim, S.R.2
McDonald III, A.W.3
-
25
-
-
77954621044
-
Functional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophrenia
-
Harvey PO, Armony J, Malla A, Lepage M. Functional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophrenia. J Psychiatr Res. 2010;44(11):707-716.
-
(2010)
J Psychiatr Res.
, vol.44
, Issue.11
, pp. 707-716
-
-
Harvey, P.O.1
Armony, J.2
Malla, A.3
Lepage, M.4
-
26
-
-
30344455038
-
Dysfunction of ventral striatal reward prediction in schizophrenia
-
Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29(2): 409-416.
-
(2006)
Neuroimage.
, vol.29
, Issue.2
, pp. 409-416
-
-
Juckel, G.1
Schlagenhauf, F.2
Koslowski, M.3
-
27
-
-
33749645423
-
Cognitive dysfunction in schizophrenia: Convergence of gamma-aminobutyric acid and glutamate alterations
-
Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63(10):1372-1376.
-
(2006)
Arch Neurol.
, vol.63
, Issue.10
, pp. 1372-1376
-
-
Lewis, D.A.1
Moghaddam, B.2
-
28
-
-
0027406714
-
Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: Differential actions on firing pattern related to anatomical localization
-
Murase S, Mathé JM, Grenhoff J, Svensson TH. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J Neural Transm Gen Sect. 1993;91(1):13-25.
-
(1993)
J Neural Transm Gen Sect.
, vol.91
, Issue.1
, pp. 13-25
-
-
Murase, S.1
Mathé, J.M.2
Grenhoff, J.3
Svensson, T.H.4
-
29
-
-
0027458104
-
Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists
-
Witkin JM. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 1993;53(24):PL405-PL410.
-
(1993)
Life Sci.
, vol.53
, Issue.24
-
-
Witkin, J.M.1
-
30
-
-
0031712747
-
Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex
-
Takahata R, Moghaddam B. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem. 1998;71(4):1443-1449.
-
(1998)
J Neurochem.
, vol.71
, Issue.4
, pp. 1443-1449
-
-
Takahata, R.1
Moghaddam, B.2
-
31
-
-
84859100879
-
Role of thalamic projection in NMDA receptor-induced disruption of cortical slow oscillation and short-term plasticity
-
Kiss T, Hoffmann WE, Scott L, et al. Role of thalamic projection in NMDA receptor-induced disruption of cortical slow oscillation and short-term plasticity. Front Psychiatry. 2011;2:14.
-
(2011)
Front Psychiatry.
, vol.2
, pp. 14
-
-
Kiss, T.1
Hoffmann, W.E.2
Scott, L.3
-
32
-
-
0034094275
-
Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex
-
Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur J Neurosci. 2000;12(4):1420-1430.
-
(2000)
Eur J Neurosci.
, vol.12
, Issue.4
, pp. 1420-1430
-
-
Tomitaka, S.1
Tomitaka, M.2
Tolliver, B.K.3
Sharp, F.R.4
-
33
-
-
0037475156
-
Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268
-
Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience. 2003;117(3):697-706.
-
(2003)
Neuroscience.
, vol.117
, Issue.3
, pp. 697-706
-
-
Lorrain, D.S.1
Baccei, C.S.2
Bristow, L.J.3
Anderson, J.J.4
Varney, M.A.5
-
34
-
-
33645226430
-
The NIMH-MATRICS consensus statement on negative symptoms
-
Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.
-
(2006)
Schizophr Bull.
, vol.32
, Issue.2
, pp. 214-219
-
-
Kirkpatrick, B.1
Fenton, W.S.2
Carpenter Jr., W.T.3
Marder, S.R.4
-
35
-
-
84873396022
-
The Clinical Assessment Interview for Negative Symptoms (CAINS): Final development and validation
-
Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013;170(2):165-172.
-
(2013)
Am J Psychiatry.
, vol.170
, Issue.2
, pp. 165-172
-
-
Kring, A.M.1
Gur, R.E.2
Blanchard, J.J.3
Horan, W.P.4
Reise, S.P.5
-
36
-
-
84869864467
-
Next-generation negative symptom assessment for clinical trials: Validation of the Brief Negative Symptom Scale
-
Strauss GP, Keller WR, Buchanan RW, et al. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res. 2012a;142(1-3):88-92.
-
(2012)
Schizophr Res.
, vol.142
, Issue.1-3
, pp. 88-92
-
-
Strauss, G.P.1
Keller, W.R.2
Buchanan, R.W.3
-
37
-
-
0031431410
-
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
-
Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546.
-
(1997)
J Clin Psychiatry.
, vol.58
, Issue.12
, pp. 538-546
-
-
Marder, S.R.1
Davis, J.M.2
Chouinard, G.3
-
38
-
-
34548682554
-
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale
-
Levine SZ, Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J Clin Psychopharmacol. 2007;27(5): 431-436.
-
(2007)
J Clin Psychopharmacol.
, vol.27
, Issue.5
, pp. 431-436
-
-
Levine, S.Z.1
Rabinowitz, J.2
-
39
-
-
84899868447
-
Defining and measuring negative symptoms of schizophrenia in clinical trials
-
Epub 11 November (DOI: 10.1016/j.euroneuro.2013.10.016)
-
Marder SR, Kirkpatrick B. Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol. 2013; Epub 11 November (DOI: 10.1016/j.euroneuro.2013.10.016).
-
(2013)
Eur Neuropsychopharmacol.
-
-
Marder, S.R.1
Kirkpatrick, B.2
-
40
-
-
79952141373
-
Methodological issues in negative symptom trials
-
Marder SR, Daniel DG, Alphs L, Awad G. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37(2):250-254.
-
(2011)
Schizophr Bull.
, vol.37
, Issue.2
, pp. 250-254
-
-
Marder, S.R.1
Daniel, D.G.2
Alphs, L.3
Awad, G.4
-
41
-
-
84886283569
-
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
-
Marder SR, Alphs L, Anghelescu I, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013;150(2-3):328-333.
-
(2013)
Schizophr Res.
, vol.150
, Issue.2-3
, pp. 328-333
-
-
Marder, S.R.1
Alphs, L.2
Anghelescu, I.3
-
42
-
-
84863866584
-
Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment
-
Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment. Eur Psychiatry. 2012;27(6):432-436.
-
(2012)
Eur Psychiatry.
, vol.27
, Issue.6
, pp. 432-436
-
-
Hunter, R.1
Barry, S.2
-
43
-
-
84860835479
-
Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling
-
EGOFORS Initiative
-
Llorca PM, Blanc O, Samalin L, Bosia M, Cavallaro R; EGOFORS Initiative. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur Psychiatry. 2012;27(6):396-400.
-
(2012)
Eur Psychiatry.
, vol.27
, Issue.6
, pp. 396-400
-
-
Llorca, P.M.1
Blanc, O.2
Samalin, L.3
Bosia, M.4
Cavallaro, R.5
-
44
-
-
0029918481
-
What are the functional consequences of neurocognitive deficits in schizophrenia?
-
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330.
-
(1996)
Am J Psychiatry.
, vol.153
, Issue.3
, pp. 321-330
-
-
Green, M.F.1
-
45
-
-
24944456746
-
Patient outcomes in schizophrenia I: Correlates with sociodemographic variables, psychopathology, and side effects
-
Hofer A, Baumgartner S, Edlinger M, et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry. 2005;20(5-6):386-394.
-
(2005)
Eur Psychiatry.
, vol.20
, Issue.5-6
, pp. 386-394
-
-
Hofer, A.1
Baumgartner, S.2
Edlinger, M.3
-
46
-
-
33846276906
-
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
-
Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080-2089.
-
(2006)
Am J Psychiatry.
, vol.163
, Issue.12
, pp. 2080-2089
-
-
Rosenheck, R.A.1
Leslie, D.L.2
Sindelar, J.3
-
47
-
-
84860834493
-
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data
-
Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1-3):147-150.
-
(2012)
Schizophr Res.
, vol.137
, Issue.1-3
, pp. 147-150
-
-
Rabinowitz, J.1
Levine, S.Z.2
Garibaldi, G.3
Bugarski-Kirola, D.4
Berardo, C.G.5
Kapur, S.6
-
48
-
-
84886238591
-
Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis
-
Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis. Schizophr Res. 2013;150(2-3):339-342.
-
(2013)
Schizophr Res.
, vol.150
, Issue.2-3
, pp. 339-342
-
-
Rabinowitz, J.1
Berardo, C.G.2
Bugarski-Kirola, D.3
Marder, S.4
-
49
-
-
14844321950
-
Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up
-
Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495-506.
-
(2005)
Am J Psychiatry.
, vol.162
, Issue.3
, pp. 495-506
-
-
Milev, P.1
Ho, B.C.2
Arndt, S.3
Andreasen, N.C.4
-
50
-
-
80052633733
-
Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits
-
Foussias G, Mann S, Zakzanis KK, van Reekum R, Agid O, Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr Res. 2011;132(1):24-27.
-
(2011)
Schizophr Res.
, vol.132
, Issue.1
, pp. 24-27
-
-
Foussias, G.1
Mann, S.2
Zakzanis, K.K.3
van Reekum, R.4
Agid, O.5
Remington, G.6
-
51
-
-
70349432151
-
Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptoms
-
Leifker FR, Bowie CR, Harvey PD. Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res. 2009;115(1):82-87.
-
(2009)
Schizophr Res.
, vol.115
, Issue.1
, pp. 82-87
-
-
Leifker, F.R.1
Bowie, C.R.2
Harvey, P.D.3
-
52
-
-
84875236131
-
Self-efficacy and functional status in schizophrenia: Relationship to insight, cognition and negative symptoms
-
Kurtz MM, Olfson RH, Rose J. Self-efficacy and functional status in schizophrenia: relationship to insight, cognition and negative symptoms. Schizophr Res. 2013;145(1-3):69-74.
-
(2013)
Schizophr Res.
, vol.145
, Issue.1-3
, pp. 69-74
-
-
Kurtz, M.M.1
Olfson, R.H.2
Rose, J.3
-
53
-
-
0024393725
-
Negative symptoms and emotions in schizophrenia
-
Bouricius JK. Negative symptoms and emotions in schizophrenia. Schizophr Bull. 1989;15(2):201-208.
-
(1989)
Schizophr Bull.
, vol.15
, Issue.2
, pp. 201-208
-
-
Bouricius, J.K.1
-
54
-
-
0027185943
-
Psychosocial functioning and subjective experience in schizophrenia
-
Brekke JS, Levin S, Wolkon GH, Sobel E, Slade E. Psychosocial functioning and subjective experience in schizophrenia. Schizophr Bull. 1993;19(3):599-608.
-
(1993)
Schizophr Bull.
, vol.19
, Issue.3
, pp. 599-608
-
-
Brekke, J.S.1
Levin, S.2
Wolkon, G.H.3
Sobel, E.4
Slade, E.5
-
55
-
-
80052793580
-
Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia
-
Erickson M, Jaafari N, Lysaker P. Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia. Psychiatry Res. 2011;189(2):161-165.
-
(2011)
Psychiatry Res.
, vol.189
, Issue.2
, pp. 161-165
-
-
Erickson, M.1
Jaafari, N.2
Lysaker, P.3
-
56
-
-
0028920148
-
Negative symptoms and vocational impairment in schizophrenia: Repeated measurements of work performance over six months
-
Lysaker P, Bell M. Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatr Scand. 1995;91(3):205-208.
-
(1995)
Acta Psychiatr Scand.
, vol.91
, Issue.3
, pp. 205-208
-
-
Lysaker, P.1
Bell, M.2
-
57
-
-
75749144324
-
Longitudinal associations between negative symptoms and social functioning in schizophrenia: The moderating role of employment status and setting
-
Weinberg D, Shahar G, Davidson L, McGlashan TH, Fennig S. Longitudinal associations between negative symptoms and social functioning in schizophrenia: the moderating role of employment status and setting. Psychiatry. 2009;72(4):370-381.
-
(2009)
Psychiatry.
, vol.72
, Issue.4
, pp. 370-381
-
-
Weinberg, D.1
Shahar, G.2
Davidson, L.3
McGlashan, T.H.4
Fennig, S.5
-
58
-
-
84868201269
-
Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia
-
Strauss GP, Sandt AR, Catalano LT, Allen DN. Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia. Compr Psychiatry. 2012b;53(8):1137-1144.
-
(2012)
Compr Psychiatry.
, vol.53
, Issue.8
, pp. 1137-1144
-
-
Strauss, G.P.1
Sandt, A.R.2
Catalano, L.T.3
Allen, D.N.4
-
59
-
-
80052216057
-
Negative symptoms and social cognition: Identifying targets for psychological interventions
-
Lincoln TM, Mehl S, Kesting ML, Rief W. Negative symptoms and social cognition: identifying targets for psychological interventions. Schizophr Bull. 2011;37(suppl 2):S23-S32.
-
(2011)
Schizophr Bull.
, vol.37
, Issue.SUUPL. 2
-
-
Lincoln, T.M.1
Mehl, S.2
Kesting, M.L.3
Rief, W.4
-
60
-
-
84865077433
-
Predictors of quality of life in inpatients with schizophrenia
-
Fujimaki K, Morinobu S, Yamashita H, Takahashi T, Yamawaki S. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012;197(3):199-205.
-
(2012)
Psychiatry Res.
, vol.197
, Issue.3
, pp. 199-205
-
-
Fujimaki, K.1
Morinobu, S.2
Yamashita, H.3
Takahashi, T.4
Yamawaki, S.5
-
61
-
-
33845797866
-
Negative symptoms of schizophrenia: A problem that will not go away
-
Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatrica Scand. 2007;115(1):4-11.
-
(2007)
Acta Psychiatrica Scand.
, vol.115
, Issue.1
, pp. 4-11
-
-
Stahl, S.M.1
Buckley, P.F.2
-
62
-
-
0032811066
-
Predictors of burden and infectious illness in schizophrenia caregivers
-
Dyck DG, Short R, Vitaliano PP. Predictors of burden and infectious illness in schizophrenia caregivers. Psychosom Med. 1999;61(4):411-419.
-
(1999)
Psychosom Med.
, vol.61
, Issue.4
, pp. 411-419
-
-
Dyck, D.G.1
Short, R.2
Vitaliano, P.P.3
-
63
-
-
0030854159
-
Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia
-
Provencher HL, Mueser KT. Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia. Schizophr Res. 1997;26(1):71-80.
-
(1997)
Schizophr Res.
, vol.26
, Issue.1
, pp. 71-80
-
-
Provencher, H.L.1
Mueser, K.T.2
-
64
-
-
84869863703
-
Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia
-
Braw Y, Benozio A, Levkovitz Y. Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia. Schizophr Res. 2012;142(1-3):122-128.
-
(2012)
Schizophr Res.
, vol.142
, Issue.1-3
, pp. 122-128
-
-
Braw, Y.1
Benozio, A.2
Levkovitz, Y.3
-
65
-
-
60549091905
-
Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study
-
Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108(1-3):223-230.
-
(2009)
Schizophr Res.
, vol.108
, Issue.1-3
, pp. 223-230
-
-
Novick, D.1
Haro, J.M.2
Suarez, D.3
Vieta, E.4
Naber, D.5
-
66
-
-
84871932147
-
Attaining and sustaining remission of predominant negative symptoms
-
Levine SZ, Leucht S. Attaining and sustaining remission of predominant negative symptoms. Schizophr Res. 2013;143(1):60-64.
-
(2013)
Schizophr Res.
, vol.143
, Issue.1
, pp. 60-64
-
-
Levine, S.Z.1
Leucht, S.2
-
67
-
-
79955429050
-
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology
-
Schizophrenia Consensus Group of British Association for Psychopharmacology
-
Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
-
(2011)
J Psychopharmacol.
, vol.25
, Issue.5
, pp. 567-620
-
-
Barnes, T.R.1
-
68
-
-
77956864079
-
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis
-
Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197(3):174-179.
-
(2010)
Br J Psychiatry.
, vol.197
, Issue.3
, pp. 174-179
-
-
Singh, S.P.1
Singh, V.2
Kar, N.3
Chan, K.4
-
70
-
-
84856270110
-
Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis
-
Hecht EM, Landy DC. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res. 2012;134(2-3):202-206.
-
(2012)
Schizophr Res.
, vol.134
, Issue.2-3
, pp. 202-206
-
-
Hecht, E.M.1
Landy, D.C.2
-
71
-
-
13444271621
-
Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia
-
Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162(2):388-390.
-
(2005)
Am J Psychiatry.
, vol.162
, Issue.2
, pp. 388-390
-
-
Bodkin, J.A.1
Siris, S.G.2
Bermanzohn, P.C.3
Hennen, J.4
Cole, J.O.5
-
72
-
-
40549123370
-
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
-
Amiri A, Noorbala AA, Nejatisafa AA, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol. 2008;23(2):79-86.
-
(2008)
Hum Psychopharmacol.
, vol.23
, Issue.2
, pp. 79-86
-
-
Amiri, A.1
Noorbala, A.A.2
Nejatisafa, A.A.3
-
73
-
-
0036458393
-
Amisulpride: Is there a treatment for negative symptoms in schizophrenia patients?
-
Storosum JG, Elferink AJ, van Zwieten BJ, van Strik R, Hoogendijk WJ, Broekmans AW. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull. 2002;28(2):193-201.
-
(2002)
Schizophr Bull.
, vol.28
, Issue.2
, pp. 193-201
-
-
Storosum, J.G.1
Elferink, A.J.2
van Zwieten, B.J.3
van Strik, R.4
Hoogendijk, W.J.5
Broekmans, A.W.6
-
74
-
-
70449641202
-
Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?
-
Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39: 1591-1602.
-
(2009)
Psychol Med.
, vol.39
, pp. 1591-1602
-
-
Leucht, S.1
Kissling, W.2
Davis, J.M.3
-
75
-
-
84886297495
-
Pharmacological approaches to treating negative symptoms: A review of clinical trials
-
Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: A review of clinical trials. Schizophr Res. 2013;150(2-3):346-352.
-
(2013)
Schizophr Res.
, vol.150
, Issue.2-3
, pp. 346-352
-
-
Arango, C.1
Garibaldi, G.2
Marder, S.R.3
-
76
-
-
84900405461
-
-
National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. National Clinical Guideline Number 82. Leicester, UK: The British Psychological Society and The Royal College of Psychiatrists
-
National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition). National Clinical Guideline Number 82. Leicester, UK: The British Psychological Society and The Royal College of Psychiatrists; 2010.
-
(2010)
The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition).
-
-
-
77
-
-
84855339931
-
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia
-
Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36-45.
-
(2012)
J Clin Psychopharmacol.
, vol.32
, Issue.1
, pp. 36-45
-
-
Buchanan, R.W.1
Panagides, J.2
Zhao, J.3
-
78
-
-
84886251333
-
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis
-
Potkin SG, Phiri P, Szegedi A, Zhao J, Alphs L, Cazorla P. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis. Schizophr Res. 2013;150(2-3):442-449.
-
(2013)
Schizophr Res.
, vol.150
, Issue.2-3
, pp. 442-449
-
-
Potkin, S.G.1
Phiri, P.2
Szegedi, A.3
Zhao, J.4
Alphs, L.5
Cazorla, P.6
-
80
-
-
84900411478
-
Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study
-
Epub 2 April (DOI: 10.1001/jamapsychiatry.2014.163)
-
Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014; Epub 2 April (DOI: 10.1001/jamapsychiatry.2014.163).
-
(2014)
JAMA Psychiatry.
-
-
Umbricht, D.1
Alberati, D.2
Martin-Facklam, M.3
-
81
-
-
77949447469
-
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis
-
Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522-537.
-
(2010)
Curr Pharm Des.
, vol.16
, Issue.5
, pp. 522-537
-
-
Tsai, G.E.1
Lin, P.Y.2
-
82
-
-
80052996482
-
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia
-
Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10): 859-885.
-
(2011)
CNS Drugs.
, vol.25
, Issue.10
, pp. 859-885
-
-
Singh, S.P.1
Singh, V.2
-
83
-
-
1542617755
-
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
-
Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55(5):452-456.
-
(2004)
Biol Psychiatry.
, vol.55
, Issue.5
, pp. 452-456
-
-
Tsai, G.1
Lane, H.Y.2
Yang, P.3
Chong, M.Y.4
Lange, N.5
-
84
-
-
27744529018
-
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study
-
Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196-1204.
-
(2005)
Arch Gen Psychiatry.
, vol.62
, Issue.11
, pp. 1196-1204
-
-
Lane, H.Y.1
Chang, Y.C.2
Liu, Y.C.3
Chiu, C.C.4
Tsai, G.E.5
-
85
-
-
33748751382
-
Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
-
Lane HY, Huang CL, Wu PL, et al. Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645-649.
-
(2006)
Biol Psychiatry.
, vol.60
, Issue.6
, pp. 645-649
-
-
Lane, H.Y.1
Huang, C.L.2
Wu, P.L.3
-
86
-
-
36849071470
-
Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study
-
Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9-12.
-
(2008)
Biol Psychiatry.
, vol.63
, Issue.1
, pp. 9-12
-
-
Lane, H.Y.1
Liu, Y.C.2
Huang, C.L.3
-
87
-
-
77953545879
-
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
-
Lane HY, Lin CH, Huang YJ, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451-460.
-
(2010)
Int J Neuropsychopharmacol.
, vol.13
, Issue.4
, pp. 451-460
-
-
Lane, H.Y.1
Lin, C.H.2
Huang, Y.J.3
-
88
-
-
0036641749
-
D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
-
Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002;56(1-2):19-23.
-
(2002)
Schizophr Res.
, vol.56
, Issue.1-2
, pp. 19-23
-
-
Evins, A.E.1
Amico, E.2
Posever, T.A.3
Toker, R.4
Goff, D.C.5
-
89
-
-
0348047434
-
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis
-
Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res. 2004;66:89-96.
-
(2004)
Schizophr Res.
, vol.66
, pp. 89-96
-
-
Heresco-Levy, U.1
Javitt, D.C.2
-
90
-
-
0029658545
-
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
-
Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996;169:610-617.
-
(1996)
Br J Psychiatry.
, vol.169
, pp. 610-617
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ermilov, M.3
-
91
-
-
0032925438
-
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
-
Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56(1):29-36.
-
(1999)
Arch Gen Psychiatry.
, vol.56
, Issue.1
, pp. 29-36
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ermilov, M.3
-
92
-
-
0028015607
-
Amelioration of negative symptoms in schizophrenia by glycine
-
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994;151(8):1234-1236.
-
(1994)
Am J Psychiatry.
, vol.151
, Issue.8
, pp. 1234-1236
-
-
Javitt, D.C.1
Zylberman, I.2
Zukin, S.R.3
Heresco-Levy, U.4
Lindenmayer, J.P.5
-
93
-
-
84890018607
-
Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor
-
Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of d-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70(12): 1267-1275.
-
(2013)
JAMA Psychiatry.
, vol.70
, Issue.12
, pp. 1267-1275
-
-
Lane, H.Y.1
Lin, C.H.2
Green, M.F.3
-
94
-
-
84886304673
-
Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
-
Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150(2-3):434-441.
-
(2013)
Schizophr Res.
, vol.150
, Issue.2-3
, pp. 434-441
-
-
Stauffer, V.L.1
Millen, B.A.2
Andersen, S.3
-
95
-
-
84900391079
-
-
Presented at 68th Annual Scientific Convention of Society of Biological Psychiatry; May 16-18, San Francisco, CA
-
De Boer P, Sinha V, Hoeben E, et al. Characterization of the clinical effect of a positive allosteric modulator of the metabotropic glutamate receptor-2 [poster #998]. Presented at 68th Annual Scientific Convention of Society of Biological Psychiatry; May 16-18, 2013; San Francisco, CA.
-
(2013)
Characterization of the clinical effect of a positive allosteric modulator of the metabotropic glutamate receptor-2 [poster #998].
-
-
De Boer, P.1
Sinha, V.2
Hoeben, E.3
-
97
-
-
84878590414
-
A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia
-
Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38(6):968-975.
-
(2013)
Neuropsychopharmacology.
, vol.38
, Issue.6
, pp. 968-975
-
-
Lieberman, J.A.1
Dunbar, G.2
Segreti, A.C.3
-
98
-
-
84881027906
-
Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy
-
Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophr Res. 2013;148(1-3):138-144.
-
(2013)
Schizophr Res.
, vol.148
, Issue.1-3
, pp. 138-144
-
-
Deutsch, S.I.1
Schwartz, B.L.2
Schooler, N.R.3
Brown, C.H.4
Rosse, R.B.5
Rosse, S.M.6
-
99
-
-
84883472062
-
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy
-
Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013;203:172-178.
-
(2013)
Br J Psychiatry.
, vol.203
, pp. 172-178
-
-
Choi, K.H.1
Wykes, T.2
Kurtz, M.M.3
-
101
-
-
84884288999
-
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: Open-label and randomized-withdrawal phases
-
Lasser RA, Dirks B, Nasrallah H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013;38(11):2140-2149.
-
(2013)
Neuropsychopharmacology.
, vol.38
, Issue.11
, pp. 2140-2149
-
-
Lasser, R.A.1
Dirks, B.2
Nasrallah, H.3
-
102
-
-
84878967787
-
A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities
-
Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013;147(2-3):241-252.
-
(2013)
Schizophr Res.
, vol.147
, Issue.2-3
, pp. 241-252
-
-
Lindenmayer, J.P.1
Nasrallah, H.2
Pucci, M.3
James, S.4
Citrome, L.5
-
103
-
-
84998166025
-
A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia
-
Wittkampf LC, Arends J, Timmerman L, Lancel M. A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia. Ther Adv Psychopharmacol. 2012;2(3): 115-125.
-
(2012)
Ther Adv Psychopharmacol.
, vol.2
, Issue.3
, pp. 115-125
-
-
Wittkampf, L.C.1
Arends, J.2
Timmerman, L.3
Lancel, M.4
-
104
-
-
48749112603
-
N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial
-
Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361-368.
-
(2008)
Biol Psychiatry.
, vol.64
, Issue.5
, pp. 361-368
-
-
Berk, M.1
Copolov, D.2
Dean, O.3
-
105
-
-
84864999825
-
Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment
-
Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26(9):1185-1193.
-
(2012)
J Psychopharmacol.
, vol.26
, Issue.9
, pp. 1185-1193
-
-
Chaudhry, I.B.1
Hallak, J.2
Husain, N.3
-
106
-
-
77649112679
-
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
-
Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138-149.
-
(2010)
J Clin Psychiatry.
, vol.71
, Issue.2
, pp. 138-149
-
-
Levkovitz, Y.1
Mendlovich, S.2
Riwkes, S.3
-
107
-
-
84894226297
-
Selective serotonin 3 receptor antagonist treatment for schizophrenia: Meta-analysis and systematic review
-
Kishi T, Mukai T, Matsuda Y, Iwata N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: Meta-analysis and systematic review. Neuromolecular Med. 2014;16(1):61-69.
-
(2014)
Neuromolecular Med.
, vol.16
, Issue.1
, pp. 61-69
-
-
Kishi, T.1
Mukai, T.2
Matsuda, Y.3
Iwata, N.4
-
108
-
-
62649086513
-
The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
-
Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109(1-3):10-14.
-
(2009)
Schizophr Res.
, vol.109
, Issue.1-3
, pp. 10-14
-
-
Tiihonen, J.1
Wahlbeck, K.2
Kiviniemi, V.3
-
109
-
-
84880133046
-
NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials
-
Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013;47(9):1143-1149.
-
(2013)
J Psychiatr Res.
, vol.47
, Issue.9
, pp. 1143-1149
-
-
Kishi, T.1
Iwata, N.2
-
110
-
-
62349116484
-
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
-
for the MEM-MD-29 Study Group
-
Lieberman JA, Papadakis K, Csernansky J, et al; for the MEM-MD-29 Study Group. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009;34(5):1322-1329.
-
(2009)
Neuropsychopharmacology.
, vol.34
, Issue.5
, pp. 1322-1329
-
-
Lieberman, J.A.1
Papadakis, K.2
Csernansky, J.3
-
111
-
-
67449123074
-
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia
-
Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34(8): 1885-1903.
-
(2009)
Neuropsychopharmacology.
, vol.34
, Issue.8
, pp. 1885-1903
-
-
Marx, C.E.1
Keefe, R.S.2
Buchanan, R.W.3
-
112
-
-
80052258839
-
Pregnenolone as a novel therapeutic candidate in schizophrenia: Emerging preclinical and clinical evidence
-
Marx CE, Bradford DW, Hamer RM, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 2011;191:78-90.
-
(2011)
Neuroscience.
, vol.191
, pp. 78-90
-
-
Marx, C.E.1
Bradford, D.W.2
Hamer, R.M.3
-
113
-
-
59449098930
-
A placebo-controlled study of sildenafil effects on cognition in schizophrenia
-
Goff DC, Cather C, Freudenreich O, et al. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology. 2009;202(1-3):411-417.
-
(2009)
Psychopharmacology.
, vol.202
, Issue.1-3
, pp. 411-417
-
-
Goff, D.C.1
Cather, C.2
Freudenreich, O.3
-
114
-
-
79952487439
-
Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled trial
-
Akhondzadeh S, Ghayyoumi R, Rezaei F, et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology. 2011;213(4):809-815.
-
(2011)
Psychopharmacology.
, vol.213
, Issue.4
, pp. 809-815
-
-
Akhondzadeh, S.1
Ghayyoumi, R.2
Rezaei, F.3
-
115
-
-
84876925332
-
Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia
-
Roffman JL, Lamberti JS, Achtyes E, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70(5):481-489.
-
(2013)
JAMA Psychiatry.
, vol.70
, Issue.5
, pp. 481-489
-
-
Roffman, J.L.1
Lamberti, J.S.2
Achtyes, E.3
-
116
-
-
84864628174
-
D-serine and schizophrenia: An update
-
Nunes EA, MacKenzie EM, Rossolatos D, Perez-Parada J, Baker GB, Dursun SM. D-serine and schizophrenia: an update. Expert Rev Neurother. 2012;12(7):801-812.
-
(2012)
Expert Rev Neurother.
, vol.12
, Issue.7
, pp. 801-812
-
-
Nunes, E.A.1
McKenzie, E.M.2
Rossolatos, D.3
Perez-Parada, J.4
Baker, G.B.5
Dursun, S.M.6
-
117
-
-
84884229725
-
Glycine reuptake inhibition: A promising therapeutic strategy in the treatment of schizophrenia?
-
Chue P, Baker GB. Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia? Future Med Chem. 2013;5(13):1475-1477.
-
(2013)
Future Med Chem.
, vol.5
, Issue.13
, pp. 1475-1477
-
-
Chue, P.1
Baker, G.B.2
-
118
-
-
84876735618
-
Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1)
-
Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des. 2013;19(7):1311-1320.
-
(2013)
Curr Pharm Des.
, vol.19
, Issue.7
, pp. 1311-1320
-
-
Chue, P.1
-
119
-
-
77956648156
-
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
-
Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83:108-121.
-
(2010)
Brain Res Bull.
, vol.83
, pp. 108-121
-
-
Kantrowitz, J.T.1
Javitt, D.C.2
-
120
-
-
84900414433
-
-
Hoffmann-La Roche. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated January 6, 2014]. Available from NLM identifier: NCT01192906. Accessed March 10, 2014
-
Hoffmann-La Roche. A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 6, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192906. NLM identifier: NCT01192906. Accessed March 10, 2014.
-
(2010)
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309).
-
-
-
121
-
-
84900414433
-
-
Hoffmann-La Roche. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated March 3, 2014]. Available from. NLM identifier: NCT01192880. Accessed March 10, 2014
-
Hoffmann-La Roche. A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated March 3, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192880?term=NCT01192880&rank=1. NLM identifier: NCT01192880. Accessed March 10, 2014.
-
(2010)
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308).
-
-
-
122
-
-
84900416942
-
-
Hoffmann-La Roche. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated January 13, 2014]. Available from NLM identifier: NCT01192867. Accessed March 10, 2104
-
Hoffmann-La Roche. A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192867?term=NCT01192867&rank=1. NLM identifier: NCT01192867. Accessed March 10, 2104.
-
(2010)
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310).
-
-
-
123
-
-
84900412998
-
-
Hoffmann-La Roche. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated March 3, 2014]. Available from NLM identifier: NCT01235559. Accessed March 3, 2014
-
Hoffmann-La Roche. A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated March 3, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235559?term=nCT01235559&rank=1. NLM identifier: NCT01235559. Accessed March 3, 2014.
-
(2010)
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305).
-
-
-
124
-
-
84900412998
-
-
In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated March 3, 2014]. Hoffmann-La Roche. Available from NLM identifier: NCT01235585. Accessed March 10, 2014
-
Hoffmann-La Roche. A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated March 3, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235585?term=NCT01235585&rank=1. NLM identifier: NCT01235585. Accessed March 10, 2014.
-
(2010)
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306).
-
-
-
125
-
-
84900402337
-
-
Hoffmann-La Roche. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 20, 2014]. Available from NLM identifier: NCT01235520. Accessed March 10, 2014
-
Hoffmann-La Roche. A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 20, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235520?term=NCT01235520&rank=1. NLM identifier: NCT01235520. Accessed March 10, 2014.
-
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307).
-
-
-
126
-
-
84900446228
-
Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics-Results from the Phase III DayLyte study
-
Poster presented at: April 5-9, Florence, Italy
-
Arango C, Nasrallah H, Lawrie S, et al. Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics-Results from the Phase III DayLyte study. Poster presented at: 4th Biennial Schizophrenia International Research Society Conference, April 5-9, 2014, Florence, Italy.
-
(2014)
4th Biennial Schizophrenia International Research Society Conference
-
-
Arango, C.1
Nasrallah, H.2
Lawrie, S.3
-
127
-
-
84900433651
-
Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics-Results from the Phase III FlashLyte study
-
Poster presented at: April 5-9, Florence, Italy
-
Blaettler T, Bugarski-Kirola D, Fleischhacker W, et al. Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics-Results from the Phase III FlashLyte study. Poster presented at: 4th Biennial Schizophrenia International Research Society Conference, April 5-9, 2014, Florence, Italy.
-
(2014)
4th Biennial Schizophrenia International Research Society Conference
-
-
Blaettler, T.1
Bugarski-Kirola, D.2
Fleischhacker, W.3
-
128
-
-
84900424635
-
Efficacy and Safety of Adjunctive Bitopertin versus Placebo in Subjects with Persistent Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics-Update from the SearchLyte Programme
-
Bugarski-Kirola D, Arango C, Fleischhacker W, et al. Efficacy and Safety of Adjunctive Bitopertin versus Placebo in Subjects with Persistent Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics-Update from the SearchLyte Programme. Schizophr Res. 2014;153(Suppl 1):S29.
-
(2014)
Schizophr Res.
, vol.153
, Issue.SUUPL. 1
-
-
Bugarski-Kirola, D.1
Arango, C.2
Fleischhacker, W.3
-
129
-
-
84900420231
-
-
Janssen Research & Development, LLC. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated December 24, 2013]. Available from NLM identifier: NCT01323205. Accessed March 10, 2014
-
Janssen Research & Development, LLC. Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated December 24, 2013]. Available from http://clinicaltrials.gov/show/NCT01323205. NLM identifier: NCT01323205. Accessed March 10, 2014.
-
(2011)
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia.
-
-
-
130
-
-
84900424781
-
-
EnVivo Pharmaceuticals, Inc. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated February 12, 2014]. Available from NLM identifier: NCT01714661. Accessed March 10, 2014
-
EnVivo Pharmaceuticals, Inc. Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated February 12, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01714661?term=NCT01714661&rank=1. NLM identifier: NCT01714661. Accessed March 10, 2014.
-
(2012)
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
-
-
-
131
-
-
84900388567
-
-
EnVivo Pharmaceuticals, Inc. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated February 12, 2014]. Available from NLM identifier: NCT01714713. Accessed March 10, 2014
-
EnVivo Pharmaceuticals, Inc. A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated February 12, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01714713?term=NCT01714713&rank=1. NLM identifier: NCT01714713. Accessed March 10, 2014.
-
(2012)
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
-
-
-
132
-
-
84900455450
-
-
Targacept Inc. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated December 6, 2013]. Available from NLM identifier: NCT01488929. Accessed March 10, 2014
-
Targacept Inc. Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated December 6, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01488929?term=NCT01488929&rank=1. NLM identifier: NCT01488929. Accessed March 10, 2014.
-
(2011)
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia.
-
-
-
134
-
-
84892647238
-
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update
-
Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophr Bull. 2014;40(1):181-191.
-
(2014)
Schizophr Bull.
, vol.40
, Issue.1
, pp. 181-191
-
-
Sommer, I.E.1
van Westrhenen, R.2
Begemann, M.J.3
de Witte, L.D.4
Leucht, S.5
Kahn, R.S.6
-
135
-
-
78249290706
-
Qualitative methods in early-phase drug trials: Broadening the scope of data and methods from and RCT of N-acetylcysteine in schizophrenia
-
Berk M, Munib A, Dean O, et al. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from and RCT of N-acetylcysteine in schizophrenia. J Clin Psychiatry. 2011;72(7): 909-913.
-
(2011)
J Clin Psychiatry.
, vol.72
, Issue.7
, pp. 909-913
-
-
Berk, M.1
Munib, A.2
Dean, O.3
-
136
-
-
79953111745
-
N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action
-
Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78-86.
-
(2011)
J Psychiatry Neurosci.
, vol.36
, Issue.2
, pp. 78-86
-
-
Dean, O.1
Giorlando, F.2
Berk, M.3
|